Epistatic and functional interactions of catechol-o-methyltransferase (COMT) and AKT1 on neuregulin1-ErbB signaling

Yoshitatsu Sei1, Zhen Li, Jian Song

  • 1Clinical Brain Disorder Branch, Genes, Cognition, and Psychosis Program, National Institute of Mental Health, National Institutes of Health, Bethesda, Maryland, USA. seiy@mail.nih.gov

Plos One
|June 4, 2010
PubMed
Abstract

Insights

Catechol-O-methyltransferase (COMT) enzyme activity influences AKT1 activation and cell migration in response to Neuregulin1 (NRG1) signaling. This interaction, mediated by phosphatidylserine synthesis, offers new insights into schizophrenia and cancer pathogenesis.

Area of Science:

  • Molecular biology
  • Neuroscience
  • Genetics

Background:

  • Neuregulin1 (NRG1)-ErbB signaling is implicated in cancer and schizophrenia.
  • NRG1-stimulated B lymphoblast migration is PI3K-AKT1 dependent and impaired in schizophrenia patients.
  • This impairment is linked to the catechol-O-methyltransferase (COMT) Val108/158Met polymorphism.

Purpose of the Study:

  • To examine AKT1 activation in NRG1-stimulated cells.
  • To explore the functional relationship between COMT and AKT1.
  • To investigate the impact of COMT genotype on NRG1-mediated signaling.

Main Methods:

  • Assessed AKT1 phosphorylation and translocation in response to NRG1.
  • Investigated genetic interactions between AKT1 and COMT.
  • Measured phosphatidylserine (PS) levels and COMT enzyme activity.
  • Utilized cell transfection and S-adenosylmethionine (SAM) administration.

Main Results:

  • NRG1-induced AKT1 phosphorylation was diminished in COMT Val carriers.
  • AKT1 translocation to the plasma membrane was impaired in Val carriers.
  • COMT activity inversely correlated with PS levels, affecting AKT1 activation and migration.
  • SAM administration rescued NRG1-induced signaling deficits.

Conclusions:

  • Genetic and functional interactions between COMT and AKT1 influence cellular responses to NRG1.
  • COMT enzyme activity impacts AKT1 function via competition for SAM in PS synthesis.
  • Findings provide novel insights into the pathogenesis of schizophrenia and ErbB-associated cancers.

Related Concept Videos

Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Drugs Affecting Neurotransmitter Release or Uptake01:21

Drugs Affecting Neurotransmitter Release or Uptake

Certain drugs can affect how neurotransmitters called catecholamines, are released or taken back up in the adrenergic neuron. They can have different effects on the body's sympathetic transmission. Reserpine, a natural compound found in the Rauwolfia shrub, blocks a transporter called vesicular monoamine transporter (VMAT), which leads to a buildup of catecholamines in the cell and reduces sympathetic transmission. Another drug called guanethidine works in multiple ways, including blocking...
Enzyme-linked Receptors01:00

Enzyme-linked Receptors

Enzyme-linked receptors are proteins that act as both receptor and enzyme, activating multiple intracellular signals. This is a large group of receptors that include the receptor tyrosine kinase (RTK) family. Many growth factors and hormones bind to and activate the RTKs.
Neurotrophin (NT) receptors are a family of RTKs, including trkA, trkB, and trkC (tropomyosin-related kinase) receptors. TrkA is specific for nerve growth factor (NGF), neurotrophin-6, and neurotrophin-7. TrkB binds...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Drugs Affecting Neurotransmitter Synthesis01:29

Drugs Affecting Neurotransmitter Synthesis

Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase, which converts...
Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl hydroxylase and factor...